News und Analysen
Wall Street Says These 2 Stocks May Double. Should You Buy Them?
One of the exciting parts of investing is identifying companies that will offer us the next big thing. This could be a game-changing drug or an exciting technology that may transform healthcare. And
Why Shares of Amedisys Are Jumping Monday
Shares of home healthcare solutions company Amedisys (NASDAQ: AMED) were up more than 14% Monday morning after the company reported that it had received an unsolicited buyout offer from Optum, a
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least
This Biotech Could Soon Go Parabolic, But Should You Buy It?
In the often-volatile world of biotech stocks, shares of small-cap Blueprint Medicines (NASDAQ: BPMC) have proven surprisingly steady over the past 12 months. But the stock could be gearing up for a
CVS Stock Just Hit a 52-Week Low. Is It Time to Buy?
CVS Health (NYSE: CVS) is a busy company. It runs the nation's largest drugstore chain with nearly 10,000 locations; it also manages prescription drug plans for employers and insurers; and, through
Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?
A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Over the past year, the company's shares are up by 17%. And Wall Street continues to be
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
People saving for retirement often dream of crossing the $1 million milestone. While it is far from obvious that this amount is enough to live out the rest of one's life comfortably, it is still a
3 Dividend Stocks You Can Buy Without Any Hesitation
Decisions, decisions. Every investor has to make them. The good news is that some decisions aren't difficult. Three Motley Fool contributors identified dividend stocks that should be easy buy
Why Shares of BioNTech Rose Friday
Shares of BioNTech (NASDAQ: BNTX) were up as by much as 5.3% on Friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its
Why Shares of Apollomics Are Up Friday
Shares of Apollomics (NASDAQ: APLM) were up more than 11% Friday morning after an analyst initiated coverage on the stock with a buy rating. The clinical-stage biopharmaceutical company focuses on
Why Victoria's Secret Stock Fell This Week
Victoria's Secret (NYSE: VSCO) shareholders lost ground to the market this week. Shares fell 14% through Thursday trading, compared to a 0.4% increase in the S&P 500. This drop added to a tough year
Why Biohaven Stock Caught Fire This Week
Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The
Acadia Healthcare Appoints Heather Dixon as Chief Financial Officer
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (“Acadia” or the “Company”) today announced Heather Dixon has been appointed Chief Financial Officer (CFO), effective July 10, 2023. Dixon succeeds
Why AbbVie and Amgen Are Moving Lower Today
Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization.
What's
Is Amgen a Good Dividend Stock?
Biotech pioneer Amgen (NASDAQ: AMGN) has several key elements of a good dividend stock. The company has raised its payout for 12 straight years, free cash flows have remained steady at a little over
Have $2,000? 2 Remarkable Growth Stocks to Buy Right Now
Regardless of your investing experience or risk tolerance, putting cash into stocks takes a certain tolerance for volatility and uncertainty. No investment has a guaranteed outcome. However, if you
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?
Shares of Sarepta Therapeutics (NASDAQ: SRPT) nosedived last week as the Food and Drug Administration (FDA) did not approve the company's gene therapy treatment, SRP-9001. Panic has been setting in
Why Pfizer Stock Is Perking Up Today
Shares of pharma titan Pfizer (NYSE: PFE) were up by 2.24% on moderate volume as of 2:29 p.m. ET Wednesday afternoon. The drugmaker's stock is trending higher despite every major U.S. stock index
Why Viking Therapeutics Stock Is Heating Up Today
Shares of the metabolic disease specialist Viking Therapeutics (NASDAQ: VKTX) were up by 6.6% on slightly below-average volume as of 1:56 p.m. ET Wednesday afternoon. The biotech's stock is heating
Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire Richer
While many investors set a retirement goal of $1 million or more, there are many factors that will impact the amount you ultimately have set away for your later years. The length of time you spend
Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
Weight-loss drugs have been surging in popularity over the past year. Even Novo Nordisk's Ozempic, which isn't approved to treat weight loss, has made for a hot trend on social media, with people
2 Incredible Growth Stocks to Buy Before the Next Bull Market
You're not alone if you're waiting with eager anticipation for the next prolonged bull market. The stock market has clocked its fair share of up and down days in the first several months of 2023
The Best Stocks to Invest $5,000 in Right Now
You don't have to outthink the market or take big risks to profit off an investment. There are plenty of good healthcare stocks with strong momentum and solid financials that make great long-term
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
CRISPR Therapeutics (NASDAQ: CRSP) has been making headlines lately as a result of its groundbreaking gene-editing collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX). The backstory is that the
2 Ultra-Safe Dividend Stocks to Load Up On Right Now
If your stock portfolio hasn't fully recovered from the 2022 bear market, you're definitely not alone. Even after the fairly strong rally in growth and value stocks during the first half of 2023